Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis

BACKGROUND: There are no head-to-head randomised controlled trials (RCTs) comparing the effectiveness of biologics in ulcerative colitis (UC). We aimed to assess the cost-effectiveness of adalimumab, infliximab and vedolizumab as first-line agents to induce clinical remission and mucosal healing (MH...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMJ Open Gastroenterol
Egile Nagusiak: Yokomizo, Lauren, Limketkai, Berkeley, Park, K T
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2016
Gaiak:
Inflammatory Bowel Disease
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4860720/
https://ncbi.nlm.nih.gov/pubmed/27195130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjgast-2016-000093
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak